Deadline approaching

Final date close for submissions to controversial drug post-marketing review  Tuesday, 6 June is the last day on which pharmacists can make a submission to a Government review that has called into question the way ezetimibe is prescribed and dispensed to patients with dyslipidemia who are inadequately controlled on, or unable to tolerate, statin therapy.